BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference on Thursday, June 5, 2025 at 12:00 p.m. (noon) Eastern time (9:00 a.m. Pacific time). Investors and interested individuals can register for the conference here. Questions from the audience during the live fireside chat will be welcomed.
Registered, qualified investors can request one-on-one meetings with Cocrystal management through the conference registration platform.
A video webcast of the presentation will be available within approximately 48 hours following the event on the Cocrystal website, and as part of a complete catalog of presentations available on Channelchek, the investor portal created by Noble. The webcast will be archived on the Company’s website and on Channelchek.com for 90 days following the event.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.64 |
| Daily Change: | -0.05 -2.96 |
| Daily Volume: | 8,833 |
| Market Cap: | US$16.680M |
June 05, 2025 April 24, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
